PhD in Bioprocess Chemistry: Therapeutic Nucleoside Editing
Listed on 2026-10-25
-
Research/Development
Research Scientist, Pharmaceutical Science/ Research, Biotechnology, Drug Discovery
The University of Manchester’s School of Chemistry invites applications for a fully funded PhD studentship in Bioprocess:
Skeletal Editing of Therapeutic Nucleosides.
This 3.5-year programme starts in 2026 and focuses on developing bioprocess strategies and skeletal editing to create novel therapeutic nucleosides, integrating synthesis, analytics, and biocatalysis within a collaborative research environment.
For the PhD in Bioprocess Chemistry:
Therapeutic Nucleoside Editing position at RFCSR, we are reviewing applications now.
The following opportunity is for a PhD in Bioprocess Chemistry:
Therapeutic Nucleoside Editing with RFCSR.
Our team is growing, and we are hiring a PhD in Bioprocess Chemistry:
Therapeutic Nucleoside Editing in Manchester, England, United Kingdom.
This opportunity is for the PhD in Bioprocess Chemistry:
Therapeutic Nucleoside Editing role at RFCSR.
We are seeking a motivated PhD in Bioprocess Chemistry:
Therapeutic Nucleoside Editing to join RFCSR in Manchester, England, United Kingdom.
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).